

Michael A Tainsky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2520067/publications.pdf>

Version: 2024-02-01

98
papers

6,605
citations

94433

37
h-index

62596

80
g-index

101
all docs

101
docs citations

101
times ranked

7542
citing authors

#	ARTICLE	IF	CITATIONS
1	Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. <i>Cell</i> , 1992, 70, 937-948.	28.9	1,116
2	Molecular cloning of a new transforming gene from a chemically transformed human cell line. <i>Nature</i> , 1984, 311, 29-33.	27.8	923
3	Role for Human SIRT2 NAD-Dependent Deacetylase Activity in Control of Mitotic Exit in the Cell Cycle. <i>Molecular and Cellular Biology</i> , 2003, 23, 3173-3185.	2.3	449
4	Onto-Tools, the toolkit of the modern biologist: Onto-Express, Onto-Compare, Onto-Design and Onto-Translate. <i>Nucleic Acids Research</i> , 2003, 31, 3775-3781.	14.5	319
5	<i>K</i> Ras gene mutation and amplification in human nonmelanoma skin cancers. <i>Molecular Carcinogenesis</i> , 1991, 4, 196-202.	2.7	250
6	Critical pathways in cellular senescence and immortalization revealed by gene expression profiling. <i>Oncogene</i> , 2008, 27, 5975-5987.	5.9	244
7	Diagnostic Markers of Ovarian Cancer by High-Throughput Antigen Cloning and Detection on Arrays. <i>Cancer Research</i> , 2006, 66, 1181-1190.	0.9	199
8	Breast cancer genetics in African Americans. <i>Cancer</i> , 2003, 97, 236-245.	4.1	153
9	Stochastic cancer progression driven by nonclonal chromosome aberrations. <i>Journal of Cellular Physiology</i> , 2006, 208, 461-472.	4.1	143
10	Loss of AP-2 Results in Up-regulation of MCAM/MUC18 and an Increase in Tumor Growth and Metastasis of Human Melanoma Cells. <i>Journal of Biological Chemistry</i> , 1998, 273, 16501-16508.	3.4	141
11	PolyADP-ribose polymerase is a coactivator for AP-2-mediated transcriptional activation. <i>Nucleic Acids Research</i> , 1999, 27, 866-874.	14.5	135
12	Epigenetic silencing of multiple interferon pathway genes after cellular immortalization. <i>Oncogene</i> , 2003, 22, 4118-4127.	5.9	127
13	Microtubule Deacetylases, SirT2 and HDAC6, in the Nervous System. <i>Neurochemical Research</i> , 2007, 32, 187-195.	3.3	117
14	Gene expression profiling of replicative and induced senescence. <i>Cell Cycle</i> , 2014, 13, 3927-3937.	2.6	91
15	N-ras oncogene causes AP-2 transcriptional self-interference, which leads to transformation.. <i>Genes and Development</i> , 1994, 8, 1258-1269.	5.9	89
16	The Li-Fraumeni Syndrome: From Clinical Epidemiology to Molecular Genetics. <i>American Journal of Epidemiology</i> , 1992, 135, 190-199.	3.4	78
17	Autoantibody Approach for Serum-Based Detection of Head and Neck Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 2396-2405.	2.5	69
18	Mutations in SIRT2 deacetylase which regulate enzymatic activity but not its interaction with HDAC6 and tubulin. <i>Molecular and Cellular Biochemistry</i> , 2007, 303, 221-230.	3.1	69

#	ARTICLE	IF	CITATIONS
19	Genomic and proteomic biomarkers for cancer: A multitude of opportunities. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2009, 1796, 176-193.	7.4	66
20	The Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor PD184352 (CI-1040) Selectively Induces Apoptosis in Malignant Schwannoma Cell Lines. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 316, 456-465.	2.5	63
21	The genomic structure of the human AP-2 transcription factor. <i>Nucleic Acids Research</i> , 1994, 22, 1413-1420.	14.5	62
22	Ethnic differences in survival among women with ovarian carcinoma. <i>Cancer</i> , 2002, 94, 1886-1893.	4.1	61
23	Elevated expression of the ribosomal protein S2 gene in human tumors. <i>Molecular Carcinogenesis</i> , 1992, 5, 219-231.	2.7	59
24	Coactivator PC4 Mediates AP-2 Transcriptional Activity and Suppresses <i>ras</i> -Induced Transformation Dependent on AP-2 Transcriptional Interference. <i>Molecular and Cellular Biology</i> , 1999, 19, 899-908.	2.3	57
25	Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot. <i>Clinical Cancer Research</i> , 2002, 8, 3910-21.	7.0	57
26	Characterization of the Activation Domains of AP-2 Family Transcription Factors. <i>Journal of Biological Chemistry</i> , 2000, 275, 29701-29708.	3.4	56
27	Epigenetic Silencing of IRF7 and/or IRF5 in Lung Cancer Cells Leads to Increased Sensitivity to Oncolytic Viruses. <i>PLoS ONE</i> , 2011, 6, e28683.	2.5	56
28	Communication and decision-making about seeking inherited cancer risk information: findings from female survivor-relative focus groups. <i>Psycho-Oncology</i> , 2006, 15, 193-208.	2.3	55
29	Noise sampling method: an ANOVA approach allowing robust selection of differentially regulated genes measured by DNA microarrays. <i>Bioinformatics</i> , 2003, 19, 1348-1359.	4.1	54
30	De Novo Ceramide Accumulation Due to Inhibition of Its Conversion to Complex Sphingolipids in Apoptotic Photosensitized Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 23238-23249.	3.4	54
31	Telomerase activity during spontaneous immortalization of Li-Fraumeni syndrome skin fibroblasts. <i>Oncogene</i> , 1998, 17, 709-717.	5.9	53
32	Evidence that Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Induction by 5-Aza-2'-Deoxycytidine Sensitizes Human Breast Cancer Cells to Adriamycin. <i>Cancer Research</i> , 2007, 67, 1203-1211.	0.9	52
33	Interferon Regulatory Factors IRF5 and IRF7 Inhibit Growth and Induce Senescence in Immortal Li-Fraumeni Fibroblasts. <i>Molecular Cancer Research</i> , 2008, 6, 770-784.	3.4	48
34	Sphingomyelin synthase 1 suppresses ceramide production and apoptosis post-photodamage. <i>Biochemical and Biophysical Research Communications</i> , 2007, 358, 196-202.	2.1	47
35	Telomere dysfunction and chromothripsis. <i>International Journal of Cancer</i> , 2016, 138, 2905-2914.	5.1	42
36	A role for manganese superoxide dismutase in apoptosis after photosensitization. <i>Biochemical and Biophysical Research Communications</i> , 2005, 332, 411-417.	2.1	40

#	ARTICLE	IF	CITATIONS
37	Update on ovarian cancer screening. <i>Current Opinion in Obstetrics and Gynecology</i> , 2007, 19, 22-26.	2.0	40
38	Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1. <i>Biochemical Pharmacology</i> , 2006, 72, 1485-1492.	4.4	39
39	Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability. <i>PLoS ONE</i> , 2017, 12, e0178450.	2.5	39
40	Epitomics: serum screening for the early detection of cancer on microarrays using complex panels of tumor antigens. <i>Expert Review of Molecular Diagnostics</i> , 2005, 5, 735-743.	3.1	37
41	Genomic instability due to germline p53 mutations drives preneoplastic Progression toward cancer in human cells. <i>Cancer and Metastasis Reviews</i> , 1995, 14, 43-48.	5.9	33
42	Aflatoxin B1-induced immortalization of cultured skin fibroblasts from a patient with Li-Fraumeni syndrome. <i>Carcinogenesis</i> , 1995, 16, 25-34.	2.8	32
43	CREG1 enhances p16 ^{INK4a} -induced cellular senescence. <i>Cell Cycle</i> , 2011, 10, 518-530.	2.6	32
44	Usage of cancer associated autoantibodies in the detection of disease. <i>Cancer Biomarkers</i> , 2010, 6, 257-270.	1.7	30
45	Cloning and characterization of the Drosophila homologue of the AP-2 transcription factor. <i>Oncogene</i> , 1998, 17, 1911-1922.	5.9	29
46	Enhanced quaternary stability of β^{24} hemoglobin in 2 m-sodium chloride. <i>Journal of Molecular Biology</i> , 1973, 75, 735-739.	4.2	26
47	Analysis of the transforming potential of the human homolog of mos. <i>Cell</i> , 1986, 46, 785-794.	28.9	26
48	Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cells by overexpression of AP-2 β . <i>Oncogene</i> , 2004, 23, 5496-5504.	5.9	26
49	Epitomics: Global Profiling of Immune Response to Disease Using Protein Microarrays. <i>OMICS A Journal of Integrative Biology</i> , 2006, 10, 499-506.	2.0	25
50	Expression Profiling Identifies Three Pathways Altered in Cellular Immortalization: Interferon, Cell Cycle, and Cytoskeleton. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2006, 61, 879-889.	3.6	24
51	Discovery of Antibody Biomarkers Using Protein Microarrays of Tumor Antigens Cloned in High Throughput. <i>Methods in Molecular Biology</i> , 2009, 520, 21-38.	0.9	23
52	drp, a Novel Protein Expressed at High Cell Density but Not During Growth Arrest. <i>DNA and Cell Biology</i> , 1998, 17, 437-447.	1.9	22
53	Breast cancer risk and germline genomic profiling of women with neurofibromatosis type 1 who developed breast cancer. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 19-27.	2.8	22
54	Analysis of the expression of human tumor antigens in ovarian cancer tissues. <i>Cancer Biomarkers</i> , 2010, 6, 33-48.	1.7	21

#	ARTICLE	IF	CITATIONS
55	Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors. <i>Oncotarget</i> , 2016, 7, 57171-57185.	1.8	21
56	Predictors of decision making in families at risk for inherited breast/ovarian cancer.. <i>Health Psychology</i> , 2009, 28, 38-47.	1.6	20
57	The current state of oncogenes and cancer: Experimental approaches for analyzing oncogenetic events in human cancer. <i>Cancer and Metastasis Reviews</i> , 1990, 9, 63-80.	5.9	19
58	Paraneoplastic antigens as biomarkers for early diagnosis of ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2017, 21, 37-44.	0.6	19
59	Autoantibodies as biomarkers for ovarian cancer. <i>Cancer Biomarkers</i> , 2011, 8, 187-201.	1.7	18
60	Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53. <i>Cancer Biomarkers</i> , 2020, 27, 407-421.	1.7	18
61	The effect of retinoic acid on chemosensitivity of PA-1 human teratocarcinoma cells and its modulation by an activatedN-ras oncogene. <i>International Journal of Cancer</i> , 1992, 51, 646-651.	5.1	17
62	FANCM, RAD1, CHEK1 and TP53I3 act as BRCA-like tumor suppressors and are mutated in hereditary ovarian cancer. <i>Cancer Genetics</i> , 2019, 235-236, 57-64.	0.4	17
63	Epigenetic and functional analysis of IGFBP3 and IGFBPrP1 in cellular immortalization. <i>Biochemical and Biophysical Research Communications</i> , 2007, 357, 785-791.	2.1	16
64	Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033. <i>Cancer Biology and Therapy</i> , 2008, 7, 1938-1946.	3.4	16
65	Molecular cloning of the Mason-Pfizer monkey virus genome: Biological characterization of genome length clones and molecular comparisons to other retroviruses. <i>Virology</i> , 1986, 153, 201-214.	2.4	14
66	Functional characterization of the interacting domains of the positive coactivator PC4 with the transcription factor AP-21±. <i>Gene</i> , 2003, 320, 155-164.	2.2	14
67	The role of neurofibromin in N-Ras mediated AP-1 regulation in malignant peripheral nerve sheath tumors. <i>Molecular and Cellular Biochemistry</i> , 2010, 344, 267-276.	3.1	14
68	Utility of paraneoplastic antigens as biomarkers for surveillance and prediction of recurrence in ovarian cancer. <i>Cancer Biomarkers</i> , 2017, 20, 369-387.	1.7	14
69	RAS/MEKâ€œIndependent Gene Expression Reveals BMP2-Related Malignant Phenotypes in the <i>Nf1</i>-Deficient MPNST. <i>Molecular Cancer Research</i> , 2013, 11, 616-627.	3.4	13
70	Assessing the Functional Bias of Commercial Microarrays Using the Onto-Compare Database. <i>BioTechniques</i> , 2003, 34, S55-S61.	1.8	13
71	Immunotheranostics: breaking tolerance in immunotherapy using tumor autoantigens identified on protein microarrays. <i>Current Opinion in Drug Discovery & Development</i> , 2006, 9, 380-5.	1.9	11
72	Docetaxel Associated Pathways in Cisplatin Resistant Head and Neck Squamous Cell Carcinoma: A Pilot Study. <i>Laryngoscope</i> , 2005, 115, 1938-1946.	2.0	10

#	ARTICLE	IF	CITATIONS
73	Direct production and purification of T7 phage display cloned proteins selected and analyzed on microarrays. <i>BioTechniques</i> , 2006, 40, 220-227.	1.8	10
74	Tumor autoantibodies as biomarkers for predicting ovarian cancer recurrence. <i>Cancer Biomarkers</i> , 2012, 11, 59-73.	1.7	10
75	Serum folate receptor $\hat{\pm}$ (sFR) in ovarian cancer diagnosis and surveillance. <i>Cancer Medicine</i> , 2019, 8, 920-927.	2.8	9
76	K3326X and Other C-Terminal BRCA2 Variants Implicated in Hereditary Cancer Syndromes: A Review. <i>Cancers</i> , 2021, 13, 447.	3.7	9
77	Antioxidant agents transiently inhibit aneuploidy progression in Li-Fraumeni cell strains. <i>Molecular Carcinogenesis</i> , 2006, 45, 141-156.	2.7	8
78	Susceptibility for N-ras-mediated transformation requires loss of tumor suppressor activity. <i>Somatic Cell and Molecular Genetics</i> , 1990, 16, 15-27.	0.7	7
79	Serum prognostic biomarkers in head and neck cancer patients. <i>Laryngoscope</i> , 2014, 124, 1819-1826.	2.0	7
80	Germline mutations in apoptosis pathway genes in ovarian cancer; the functional role of a TP53I3 (PIG3) variant in ROS production and DNA repair. <i>Cell Death Discovery</i> , 2021, 7, 62.	4.7	7
81	Stat1 Expression Is Not Sufficient to Regulate the Interferon Signaling Pathway in Cellular Immortalization. <i>Journal of Interferon and Cytokine Research</i> , 2006, 26, 14-26.	1.2	6
82	The H-ras oncogene regulates expression of 70- and 45-kDa cell-surface molecules whose expression correlates with tumor-cell immunogenicity. <i>International Journal of Cancer</i> , 1992, 52, 329-335.	5.1	4
83	Coordinate control of growth and cytokeratin 13 expression by retinoic acid. <i>Molecular Carcinogenesis</i> , 1996, 16, 6-11.	2.7	4
84	Germline and Somatic $\langle i \rangle$ NF1 $\langle /i \rangle$ Alterations Are Linked to Increased HER2 Expression in Breast Cancer. <i>Cancer Prevention Research</i> , 2018, 11, 655-664.	1.5	4
85	pZ402, an improved SV40-based shuttle vector containing a T-antigen mutant unable to interact with wild-type p53. <i>Gene</i> , 1998, 211, 229-234.	2.2	3
86	Multianalyte Tests for the Early Detection of Cancer: Speedbumps and Barriers. <i>Biomarker Insights</i> , 2007, 2, 117727190700200.	2.5	2
87	Detecting tumor-specific autoantibodies for cancer diagnosis: a technology overview. <i>Expert Opinion on Medical Diagnostics</i> , 2009, 3, 251-261.	1.6	2
88	Higher miRNA Tolerance in Immortal Li-Fraumeni Fibroblasts with Abrogated Interferon Signaling Pathway. <i>Cancer Research</i> , 2011, 71, 255-265.	0.9	2
89	Utilizing iVariantGuide for Variant Assessment of Next-Generation Sequencing. <i>Current Protocols in Bioinformatics</i> , 2019, 65, e73.	25.8	2
90	Functional analysis of ATM variants in a high risk cohort provides insight into missing heritability. <i>Cancer Genetics</i> , 2022, 264-265, 40-49.	0.4	2

#	ARTICLE	IF	CITATIONS
91	Cancer Biomarker Discovery: Speed-bumps and Tire Shredders. Cancer Biomarkers, 2010, 6, 225-227.	1.7	1
92	Molecular phenotyping of head and neck cancer. Cancer Treatment and Research, 1995, 74, 17-42.	0.5	1
93	Multianalyte tests for the early detection of cancer: speedbumps and barriers. Biomarker Insights, 2007, 2, 261-7.	2.5	1
94	Preparation of High-Molecular-Weight DNA for Use in DNA Transfection: Secondary Transfections for Cloning Active Genes by Direct Phenotypic Selection. , 1991, 7, 91-98.		0
95	Pathways to implementation of serum proteomics for cancer. Expert Opinion on Medical Diagnostics, 2007, 1, 3-15.	1.6	0
96	Preface. Cancer and Metastasis Reviews, 2015, 34, 3-3.	5.9	0
97	Spatial Detrending and Normalization Methods for Two-Channel DNA and Protein Microarray Data. Drug Discovery Series, 2008, , 61-80.	0.1	0
98	REGULATION OF DNA-DEPENDENT: RNA POLYMERASE I ACTIVITY IN RAT LIVER NUCLEI. , 1978, , 525.		0